347 related articles for article (PubMed ID: 29712861)
1. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
3. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
4. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
[TBL] [Abstract][Full Text] [Related]
5. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
6. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
[TBL] [Abstract][Full Text] [Related]
7. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
8. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
9. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
[TBL] [Abstract][Full Text] [Related]
10. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
[TBL] [Abstract][Full Text] [Related]
11. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
12. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
13. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection.
Goodwin ML; Webster HS; Wang HY; Jenks JA; Nelson CS; Tu JJ; Mangold JF; Valencia S; Pollara J; Edwards W; McLellan JS; Wrapp D; Fu TM; Zhang N; Freed DC; Wang D; An Z; Permar SR
Virology; 2020 Sep; 548():182-191. PubMed ID: 32838941
[TBL] [Abstract][Full Text] [Related]
14. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.
Perotti M; Marcandalli J; Demurtas D; Sallusto F; Perez L
PLoS Pathog; 2020 Dec; 16(12):e1009169. PubMed ID: 33370407
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.
Kauvar LM; Liu K; Park M; DeChene N; Stephenson R; Tenorio E; Ellsworth SL; Tabata T; Petitt M; Tsuge M; Fang-Hoover J; Adler SP; Cui X; McVoy MA; Pereira L
Antimicrob Agents Chemother; 2015 Mar; 59(3):1558-68. PubMed ID: 25534746
[TBL] [Abstract][Full Text] [Related]
16. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
[TBL] [Abstract][Full Text] [Related]
17. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
[TBL] [Abstract][Full Text] [Related]
19. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.
Ye X; Su H; Wrapp D; Freed DC; Li F; Yuan Z; Tang A; Li L; Ku Z; Xiong W; Jaijyan D; Zhu H; Wang D; McLellan JS; Zhang N; Fu TM; An Z
PLoS Pathog; 2020 Aug; 16(8):e1008736. PubMed ID: 32745149
[TBL] [Abstract][Full Text] [Related]
20. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
